Received Jul 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | PX7E2 | — |
An 18 years old female patient received a half dose (0.25 mL) of Bexsero.; This non-serious case was reported by a nurse via call center representative and described the occurrence of incomplete dose administered in a 18-year-old female patient who received Men B NVS (Bexsero) (batch number PX7E2, expiry date 30-SEP-2026) for prophylaxis. Previously administered products included Bexsero (received 1st dose in 2024) and Menactra. On 23-JUN-2025, the patient received the 2nd dose of Bexsero. On 23-JUN-2025, an unknown time after receiving Bexsero, the patient experienced incomplete dose administered (Verbatim: An 18 years old female patient received a half dose (0.25 mL) of Bexsero.). The outcome of the incomplete dose administered was not applicable. It was unknown if the reporter considered the incomplete dose administered to be related to Bexsero and Bexsero Pre-Filled Syringe Device. It was unknown if the company considered the incomplete dose administered to be related to Bexsero and Bexsero Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-JUN-2025 The reporter reported that on 23rd June 2025 that an 18 year old female patient received a 0.25 mL dose of Bexsero because the patient moved the arm and some of it got wasted which led to incomplete dose administered. The patient received Menactra on 2018. The first dose of Bexsero was administered in 2024. On 23rd June 2025 the patient received the half dose of Bexsero as her second dose. The reporter asked what were the recommendations, should they had to give the full dose.